Business
Oxford Biomedica broadens leading viral vector ...
Oxford Biomedica broadens leading viral vector ....
About this update from Oxford Biomedica Plc
[{"type":"text","content":"\n \n \n Oxford Biomedica broadens leading viral vector offerings by incorporating Homology Medicines’ established AAV capabilities into a newly formed AAV Manufacturing and Innovation Business in the US with Homology Medicines as 20% owner\n \n \n \n \n Oxford \n Biomedica\n broadens\n leading viral vector \n offerings\n by \n incorporating \n Homology \n Medicines\n ’\n established \n AAV capabilities\n in\n to \n a newly\n formed \n AAV Manufacturing and \n Innovation\n B\n usiness\n in the US\n with \n Homology Medicines\n as 20% owner\n \n \n \n Oxford \n Biomedica\n and \n Homology Medicines\n to establish \n Oxford \n Biomedica\n Solutions LLC\n , \n a new US\n -\n based AAV manufacturing\n and innovation \n business\n \n \n Homology Medicines\n to receive $130 million from \n Oxford \n Biomedica\n to continue to advance its three clinical program\n me\n s and genetic medicines platform\n \n \n Oxford \n Biomedica\n to invest $50 million to fund the growth of \n Oxford \n Biomedica\n Solutions \n LLC \n and \n will \n own 80%\n ,\n with \n Homology Medicines\n to own 20%\n ;\n Homology Medicines\n to\n secure preferred key customer status\n \n \n Dr\n .\n Roch Doliveux to become Interim CEO of \n Oxford \n Biomedica\n and \n John Dawson to retire as CEO and remain a Board Director of \n Oxford \n Biomedica\n \n \n Oxford \n Biomedica\n and \n Homology Medicines\n to host webcasts today to discuss the \n announcement \n \n \n \n Oxford, UK\n and Bedford, Mass\n .\n , U.S.\n – \n 2\n 8\n January\n 202\n 2\n : Oxford Biomedica plc (LSE:OXB) (“Oxford Biomedica” or “the Group”), a leading gene and cell therapy group, and Homology Medicines Inc. (Nasdaq: FIXX) (“Homology”), a genetic medicines company, announced today that the companies have agreed to establish a high-performing, full scope Adeno-Associated Virus (AAV) Manufacturing and Innovation Business in the US.\n As a result of the agreement, which is immediately accretive to the Group’s revenue growth with contribution from Homology and future customer pipeline, Oxford Biomedica will establish a presence in the US and will offer global pharmaceutical and biotechnology clients innovative manufacturing expertise in AAV and lentiviral-based cell and gene therapies. Oxford Biomedica Solutions LLC will provide access to Homology’s proven end-to-end manufacturing capabili...